Policy & Practice

View the latest content related to this topic

News Daily News

FDA Approves TAVI for Asymptomatic Patients With Severe Aortic Stenosis

The agency’s decision for the balloon-expandable Sapien 3 platform is based on groundbreaking results from EARLY TAVR.

Michael O'Riordan

May 01, 2025

Slides

See all

Presentation CTO 2025

Lessons from My First Year(s) in Practice

Presenter: Bryan Kindya

February 28, 2025

Presentation CTO 2025

Lessons from My First Year(s) in Practice

Presenter: Laura Young

February 28, 2025

Presentation CTO 2025

Lessons from My First Year(s) in Practice

Presenter: Pratik Sandesara

February 28, 2025

Presentation Controversies and Advances 2025

The role of double-blind sham-controlled trials in interventional cardiology

Presenter: Rasha Al-Lamee

January 31, 2025

Presentation Controversies and Advances 2025

The Good, the Bad and the Ugly of Clinical Trial Design

Presenter: Stuart Pocock

January 31, 2025

News

See all

News Conference News SCAI 2025

Benefits of TAVI Before Symptom Onset Not Hindered by Age: EARLY TAVR

By L.A. McKeown

May 02, 2025

News Conference News SCAI 2025

More Patient-Prosthesis Mismatch With TAVI in Women, but 5-Year Survival Unaffected

By L.A. McKeown

May 02, 2025

News Daily News

Donor Hearts Fare Better With Novel Method After Circulatory Death

By Michael O'Riordan

May 01, 2025

News Daily News

FDA Approves TAVI for Asymptomatic Patients With Severe Aortic Stenosis

By Michael O'Riordan

May 01, 2025

News Conference News CX Symposium 2025

Cost Surprises and Delayed Care in Women: BASIL-2 and BEST-CLI

By L.A. McKeown

April 30, 2025

ACC 2025

March 29

March 31, 2025

CTO 2025

February 28

March 01, 2025

THT 2025

February 11

February 13, 2025

Videos on This Topic

See all

Advertisement

Policy & Practice

FDA Approves TAVI for Asymptomatic Patients With Severe Aortic Stenosis

Slides

Lessons from My First Year(s) in Practice

Lessons from My First Year(s) in Practice

Lessons from My First Year(s) in Practice

The role of double-blind sham-controlled trials in interventional cardiology

The Good, the Bad and the Ugly of Clinical Trial Design

News

Benefits of TAVI Before Symptom Onset Not Hindered by Age: EARLY TAVR

More Patient-Prosthesis Mismatch With TAVI in Women, but 5-Year Survival Unaffected

Donor Hearts Fare Better With Novel Method After Circulatory Death

FDA Approves TAVI for Asymptomatic Patients With Severe Aortic Stenosis

Cost Surprises and Delayed Care in Women: BASIL-2 and BEST-CLI

More on This Topic

Conference Coverage

ACC 2025

CTO 2025

THT 2025

Videos on This Topic

Advertisement

Policy & Practice

Slides

News

More on This Topic

Conference Coverage

Videos on This Topic

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content